Literature DB >> 28167323

Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.

Jason Grebely1, Tracy Swan2, Matthew Hickman3, Julie Bruneau4, Philip Bruggmann5, Olav Dalgard6, Alain Litwin7, Markus Backmund8, Gregory J Dore9.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28167323      PMCID： PMC6868523          DOI： 10.1016/j.jhep.2016.12.028

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  6 in total

1.  Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.

Authors:  Jacob Lalezari; J Greg Sullivan; Peter Varunok; Edward Galen; Kris V Kowdley; Vinod Rustgi; Humberto Aguilar; Franco Felizarta; Barbara McGovern; Martin King; Akshanth R Polepally; Daniel E Cohen
Journal:  J Hepatol       Date:  2015-04-01       Impact factor: 25.083

2.  Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

Authors:  Gregory J Dore; Frederick Altice; Alain H Litwin; Olav Dalgard; Edward J Gane; Oren Shibolet; Anne Luetkemeyer; Ronald Nahass; Cheng-Yuan Peng; Brian Conway; Jason Grebely; Anita Y M Howe; Isaias N Gendrano; Erluo Chen; Hsueh-Cheng Huang; Frank J Dutko; David C Nickle; Bach-Yen Nguyen; Janice Wahl; Eliav Barr; Michael N Robertson; Heather L Platt
Journal:  Ann Intern Med       Date:  2016-08-09       Impact factor: 25.391

3.  Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.

Authors:  Jason Grebely; Stefan Mauss; Ashley Brown; Jean-Pierre Bronowicki; Massimo Puoti; David Wyles; Macky Natha; Yanni Zhu; Junming Yang; Bruce Kreter; Diana M Brainard; Chohee Yun; Val Carr; Gregory J Dore
Journal:  Clin Infect Dis       Date:  2016-08-23       Impact factor: 9.079

4.  Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.

Authors:  Jason Grebely; Gregory J Dore; Stefan Zeuzem; Richard J Aspinall; Raymond Fox; Lingling Han; John McNally; Anu Osinusi; Diana M Brainard; G Mani Subramanian; Macky Natha; Graham R Foster; Alessandra Mangia; Mark Sulkowski; Jordan J Feld
Journal:  Clin Infect Dis       Date:  2016-08-23       Impact factor: 9.079

5.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Jordan J Feld; Kris V Kowdley; Eoin Coakley; Samuel Sigal; David R Nelson; Darrell Crawford; Ola Weiland; Humberto Aguilar; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

6.  Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

Authors:  Stefan Zeuzem; Reem Ghalib; K Rajender Reddy; Paul J Pockros; Ziv Ben Ari; Yue Zhao; Deborah D Brown; Shuyan Wan; Mark J DiNubile; Bach-Yen Nguyen; Michael N Robertson; Janice Wahl; Eliav Barr; Joan R Butterton
Journal:  Ann Intern Med       Date:  2015-07-07       Impact factor: 51.598
  6 in total
  2 in total

1.  Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.

Authors:  Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta
Journal:  Int J Drug Policy       Date:  2018-04-19

2.  Practical steps to improve chronic hepatitis C treatment in people with opioid use disorder.

Authors:  Carlos Roncero; Pablo Ryan; Richard Littlewood; Juan Macías; Juan Ruiz; Pedro Seijo; Raúl Felipe Palma-Álvarez; Pablo Vega
Journal:  Hepat Med       Date:  2018-12-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.